Evidence map›Paper›PMID 41541654›Full record

ArticleMedComm2026

Obestatin Treatment Counteracts Muscle Wasting by Reactivation of Autophagy in Duchenne Muscular Dystrophy.

Icía Santos-Zas, Silvia Costas-Abalde, Andrea C Lodeiro, Fátima Fernández-Barreiro, Tania Cid-Díaz, Saúl Leal-López, Jessica González-Sánchez, Mar García-Lamela, Lucía Debasa-Corral, Carlos S Mosteiro and 7 more

Abstract read
In one paragraph

Article in MedComm, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Icía Santos-ZasGrupo De Endocrinología Celular Instituto De Investigación Sanitaria De Santiago (IDIS) Complejo Hospitalario Universitario De Santiago (CHUS), Servicio Gallego De Salud (SERGAS), Trav Santiago de Compostela Spain.ORCID https://orcid.org/0000-0002-0310-9074
Silvia Costas-AbaldeGrupo De Endocrinología Celular Instituto De Investigación Sanitaria De Santiago (IDIS) Complejo Hospitalario Universitario De Santiago (CHUS), Servicio Gallego De Salud (SERGAS), Trav Santiago de Compostela Spain.
Andrea C LodeiroGrupo De Endocrinología Celular Instituto De Investigación Sanitaria De Santiago (IDIS) Complejo Hospitalario Universitario De Santiago (CHUS), Servicio Gallego De Salud (SERGAS), Trav Santiago de Compostela Spain.
Fátima Fernández-BarreiroGrupo De Endocrinología Celular Instituto De Investigación Sanitaria De Santiago (IDIS) Complejo Hospitalario Universitario De Santiago (CHUS), Servicio Gallego De Salud (SERGAS), Trav Santiago de Compostela Spain.
Tania Cid-DíazGrupo De Endocrinología Celular Instituto De Investigación Sanitaria De Santiago (IDIS) Complejo Hospitalario Universitario De Santiago (CHUS), Servicio Gallego De Salud (SERGAS), Trav Santiago de Compostela Spain.
Saúl Leal-LópezGrupo De Investigación Traslacional En Enfermedades del Aparato Digestivo (GITEAD) IDIS, CHUS, SERGAS, Trav Santiago de Compostela Spain.
Jessica González-SánchezGrupo De Endocrinología Celular Instituto De Investigación Sanitaria De Santiago (IDIS) Complejo Hospitalario Universitario De Santiago (CHUS), Servicio Gallego De Salud (SERGAS), Trav Santiago de Compostela Spain.
Mar García-LamelaGrupo De Endocrinología Celular Instituto De Investigación Sanitaria De Santiago (IDIS) Complejo Hospitalario Universitario De Santiago (CHUS), Servicio Gallego De Salud (SERGAS), Trav Santiago de Compostela Spain.
Lucía Debasa-CorralGrupo De Endocrinología Celular Instituto De Investigación Sanitaria De Santiago (IDIS) Complejo Hospitalario Universitario De Santiago (CHUS), Servicio Gallego De Salud (SERGAS), Trav Santiago de Compostela Spain.
Carlos S MosteiroGrupo De Endocrinología Celular Instituto De Investigación Sanitaria De Santiago (IDIS) Complejo Hospitalario Universitario De Santiago (CHUS), Servicio Gallego De Salud (SERGAS), Trav Santiago de Compostela Spain.
Kamel MamchaouiInserm, Institut de Myologie, Centre de Recherche en Myologie Sorbonne Université Paris France.
Vincent MoulyInserm, Institut de Myologie, Centre de Recherche en Myologie Sorbonne Université Paris France.
Xesús CasabiellGrupo De Endocrinología Celular Instituto De Investigación Sanitaria De Santiago (IDIS) Complejo Hospitalario Universitario De Santiago (CHUS), Servicio Gallego De Salud (SERGAS), Trav Santiago de Compostela Spain.
Rosalía GallegoDepartamento De Ciencias Morfológicas USC Santiago de Compostela Spain.
José Luis RelovaGrupo De Endocrinología Celular Instituto De Investigación Sanitaria De Santiago (IDIS) Complejo Hospitalario Universitario De Santiago (CHUS), Servicio Gallego De Salud (SERGAS), Trav Santiago de Compostela Spain.
Yolanda PazosGrupo De Investigación Traslacional En Enfermedades del Aparato Digestivo (GITEAD) IDIS, CHUS, SERGAS, Trav Santiago de Compostela Spain.
Jesus P CamiñaGrupo De Endocrinología Celular Instituto De Investigación Sanitaria De Santiago (IDIS) Complejo Hospitalario Universitario De Santiago (CHUS), Servicio Gallego De Salud (SERGAS), Trav Santiago de Compostela Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The mechanisms by which muscular dystrophy-related stress is transduced to the autophagic machinery remain poorly characterized. The formulation of strategies should be based on how disruption of these processes results in the deregulation of signaling pathways that contribute to many pathological effects of the disease. In this study, we investigated the molecular mechanism by which the obestatin/GPR39 system, an autocrine signaling with anabolic impact on normal skeletal muscle, restores autophagy in Duchenne muscular dystrophy (DMD). We report that obestatin integrates 5' AMP-activated protein kinase (AMPK) and mammalian target of rapamycin complex 1 (mTORC1) signaling to control ubiquitin proteasome system (UPS), autophagy-lysosome system, and protein synthesis under dystrophic context. The posttranslational modifications of the E3 ligase NEDD4-L emerges as the main switch to activate the autophagy in response to obestatin. This includes NEDD4-L tyrosine phosphorylation and autoubiquitination, which is critical for recruiting the ubiquitin-specific protease 10 to assemble a deubiquitination complex, that orchestrates the unc-51 like autophagy activating kinase 1 (ULK1) and class III PI3K (VPS34) complexes. Reactivation of autophagy through obestatin signaling promotes the recovery of physiological skeletal muscle function. Thus, DMD conditions determine permissiveness to the activation of AMPK that sustain autophagy under anabolic conditions stablished by obestatin signaling through mTORC1.

Indexed as

autophagyDuchenne muscular dystrophyneural precursor cell expressed developmentally downregulated protein 4obestatinubiquitin‐specific protease 10

Identifiers

PMID41541654
PMCPMC12803508

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.